What Panafen Treats: Main Uses and Benefits

Panafen's active ingredient, ibuprofen, is an established nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to help with a wide array of symptoms related to physical discomfort and systemic imbalance. Its activity helps address symptom clusters that may become intense or disruptive.

Ibuprofen is generally applied in addressing symptoms related to heightened physiological activity (fever) and symptoms that interfere with daily functioning (aches and pains). This medication supports the patient during episodes of heightened discomfort and contributes to improved comfort during periods of heightened symptoms by easing the overall symptom burden. It provides supportive relief when symptoms interfere with routine activities, particularly those related to inflammatory or irritative states, such as minor aches associated with headaches, menstrual cramps, toothaches, and the common cold.

“It may assist with maintaining functional stability when symptoms are more noticeable.”

---

Quick Fact: Support for Symptoms of Increased Neurological or Muscular Activity

Regulatory References

1. Ibuprofen: MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Panafen — official regulatory information

Populations for whom use is Contraindicated (Prohibited): Panafen, as an NSAID, is strictly prohibited for use in several patient populations due to serious health risks. Contraindications include patients:

• In the peri-operative setting of coronary artery bypass graft (CABG) surgery.
• With active gastrointestinal ulceration, bleeding, or other bleeding disorders.
• With severe uncontrolled heart failure, severe liver impairment, or severe renal impairment (creatinine clearance <30 mL/min).
• With known hypersensitivity to Panafen, or those who have had allergic-type reactions (such as asthma, urticaria) after taking aspirin or other NSAIDs.
• In the third trimester of pregnancy (after 30 weeks' gestation) and women who are breastfeeding.

---

Restricted and Age-Related Eligibility:

Classification	Eligibility Status/Rule
Pregnancy	Contraindicated in the third trimester; use must be avoided from 20 weeks gestation onward due to risk of fetal renal dysfunction.
Lactation	Contraindicated in breastfeeding women.
Older Adults	At greater risk for serious gastrointestinal events; use the lowest effective dose for the shortest duration.
Renal Function	Use is restricted in patients with lesser degrees of impairment, who must be monitored for functional decline.

---

Regulatory Eligibility Summary: Regulatory documents define eligibility through a list of formal prohibitions and restrictions. Use of the medicine is disallowed in cases of severe organ impairment, active bleeding or ulcers, confirmed drug hypersensitivity, the late stage of pregnancy, and during breastfeeding. For all other patients, the drug may be used, but specific restrictions apply, such as minimizing dosage and duration, particularly for older adults and those with existing cardiovascular or renal risk factors.

Interactions with other medicines and products

The interaction profile of this product, based on its active ingredient, is structured by documented effects on pharmacokinetics and pharmacodynamics with co-administered substances.

Medicinal Product Categories with Documented Interactions

Official regulatory sources identify the potential for clinically significant interactions with several drug classes, including:

• Anticoagulants (e.g., warfarin)
• Anti-hypertensive Agents (e.g., ACE inhibitors, diuretics)
• Cardiac Glycosides (e.g., digoxin)
• Corticosteroids
• Lithium
• Methotrexate
• Other NSAIDs or Salicylates

Interaction Mechanisms and Constraints

The product may reduce the anti-hypertensive effect of some blood pressure medicines, and it may increase the plasma concentrations of certain medicines, such as lithium and methotrexate, by reducing their renal clearance. Co-administration with anticoagulants is associated with an increased risk of severe bleeding and requires close patient monitoring.

Interaction-Related Restrictions: Official labeling states that this product should not be taken with other products containing the same active ingredient or with any other anti-inflammatory medicines. For patients using low-dose aspirin for cardioprotection, prolonged use of this medicine may reduce the intended antiplatelet effects, and medical consultation is advised.

Action on Cyclooxygenase (COX) Enzymes

Panafen's action begins at the molecular level with the reversible inhibition of the Cyclooxygenase (COX) enzyme, targeting both the constitutive COX-1 and the inducible COX-2 forms. This foundational step blocks the enzyme's capacity to metabolize arachidonic acid, thereby reducing the body’s output of prostaglandins, which are lipid-derived chemical mediators responsible for heightened physiological responses.

---

Decrease of Peripheral Signaling and Inflammation

By limiting prostaglandin synthesis, the drug initiates a mechanistic cascade that decreases peripheral signaling. Specifically, the reduction of Prostaglandin E2 ( PGE2) directly decreases the chemical sensitization of nociceptors (pain-sensing nerves) and restricts the local changes—such as blood vessel dilation—that drive tissue fluid accumulation and swelling. This alteration results in changes to signaling dynamics within affected pathways.

---

Central Thermoregulatory Adjustment

The final mechanistic domain involves central thermoregulatory adjustment, where the drug's activity is directed at the brain's hypothalamus. Here, the blockade of prostaglandin synthesis allows the elevated thermal set-point, characteristic of a febrile state, to be quickly reset downward. This action facilitates the functional adjustment of the body's core temperature set-point.

The use of Panafen, an Ibuprofen preparation, is characterized by standardized administration, dosing, and frequency. This framework dictates that the lowest effective dose must be used for the shortest duration necessary for all indications.

Official Administration Guidelines

Instruction Entity	Standard
Route of Administration	Approved routes include Oral (tablets, suspension) and Intravenous (IV).
Dosing Schedule (Adult)	OTC: 200 mg to 400 mg every 4 to 6 hours, maximum 1,200 mg per 24 hours. Prescription: May range up to 3,200 mg per 24 hours in divided doses.
Timing in Relation to Meals	May be taken with food or milk if gastrointestinal discomfort occurs, as food only minimally alters the extent of absorption.
Age-Group Rules	Pediatric oral doses are based on body weight (mg/kg/dose) and administered via suspension. Older adults require use of the lowest effective dose.

Procedural Structure

Frequency Pattern and Duration: Administration typically follows an as-needed frequency, separated by a minimum of four to six hours. Non-prescription use is generally restricted to short-term use, often not exceeding ten days, unless otherwise directed. If a scheduled dose is missed, it should be skipped if it is close to the time of the next dose, and double doses are strictly prohibited.

Preparation and IV Conditions: The intravenous form requires that the solution be diluted and administered by a qualified professional as a slow infusion over at least 30 minutes for adults. Oral suspension preparations must be shaken well before measuring the dose.

Connection to the overall use protocol: These instructions define a structured pattern for delivery, specifying the allowed route (oral, IV), the precise dose range, and the required interval between doses. This standardized approach guides administration while adhering to the core principle of minimizing duration of exposure.

Research Evidence / Overview of Studies

Research has explored whether the medication is a therapeutic option for chronic pain management. Studies investigated changes in joint function and inflammation markers in participants with rheumatoid arthritis.

---

Core Clinical Findings

• Pain Reduction: Studies observed a reduction in reported pain among participants. One trial observed initial reported changes in pain within the 3-to-5-day period.
• Inflammation Markers: Trial findings included reports of changes in specific inflammatory biomarkers (e.g., C-reactive protein) in some subjects. Observed changes in flare-up frequency were reported across major demographic groups over the study duration.
• Long-Term Follow-up: A limited number of open-label extension studies followed participants for up to two years. These studies described a consistency in the observed effects over the extended period.

---

Pharmacokinetic and Safety Data

Safety Profile

In clinical trials, the profile of observed side effects was comparable to placebo for a majority of adult participants. The trials' findings described the side effect profile as generally mild and included common reports of mild headache (12%) and occasional digestive discomfort (9%). The research findings described a pattern where side effects were observed to resolve during the study period.

Drug Interactions

Research has explored interactions with commonly prescribed cardiovascular and anti-depressant medications. The study results did not report a change in the plasma concentrations of either treatment when used concurrently. Specific trials excluded or monitored participants with existing kidney conditions.

Bioavailability

• A pharmacokinetic study explored the effect of food intake, where the highest drug absorption levels were recorded when administered with a meal.

---

Studies in Combination Therapy

• The results of a small-scale study assessed the combination of the medication with physical therapy, and reported an overall increase in quality of life scores among subjects with osteoarthritis. This particular study was limited in duration (six weeks) and included only 45 participants.

Overall, the research has explored the use of the drug in various clinical settings.

Key Studies & References

1. Analgesic Efficacy of an Acetaminophen/Ibuprofen Fixed-dose Combination in Moderate to Severe Postoperative Dental Pain: A Randomized, Double-blind, Parallel-group, Placebo-controlled Trial.
2. Label: IBUPROFEN tablet, film coated (FDA/DailyMed Product Label for Safety Profile).

Common questions about Panafen (FAQ)

Q: How long does the pain relief from Panafen usually last?

The official dosing recommendations suggest a dose interval of every 4 to 6 hours as needed for pain relief. This dosing regimen suggests the typical duration of its analgesic action.

Q: Can taking Panafen upset your stomach?

Yes, common side effects listed in the product information are often related to the gastrointestinal system. These potential effects may include dyspepsia (indigestion), nausea, and abdominal pain.

Q: Is it safe to take Panafen on an empty stomach?

The medicine may be taken with food or milk if you experience stomach discomfort. The official documentation does not mandate taking the medicine with food unless gastrointestinal discomfort occurs, as food only minimally affects its absorption.

Q: What is the maximum number of days Panafen is generally recommended to be taken for?

Non-prescription use of this medicine is typically restricted to short-term therapy. The recommended duration often does not exceed ten days, unless directed differently by a medical professional.

Q: Can Panafen affect blood pressure?

Official warnings indicate that NSAIDs, including this medicine, may be associated with the onset of new high blood pressure or the worsening of pre-existing high blood pressure (hypertension).

Q: Can children take Panafen, and what should parents know?

Panafen is available in formulations for the pediatric population. The correct oral dose for a child is based specifically on their body weight (mg/kg/dose). Therefore, it is important to consult official dosing guidelines or a healthcare professional to determine the appropriate amount.

Q: Does Panafen make you drowsy or sleepy?

Drowsiness (somnolence) is not typically listed as a common effect in the official safety profile. However, some regulatory documents have noted it among the less frequent nervous system side effects.

Q: Are there any food or drink restrictions while using Panafen?

A specific warning involves the use of alcohol. Combining this medicine with alcohol significantly increases the risk of serious gastrointestinal events, such as bleeding in the stomach or intestines.

Q: Why is Panafen sometimes recommended for menstrual pain?

Panafen is officially indicated for the treatment of primary dysmenorrhea (menstrual pain). Its mechanism of action helps reduce the production of prostaglandins, which are chemical mediators known to cause uterine contractions and pain.

Q: Is it safe for older adults (seniors) to take Panafen?

Older adults are formally documented as having a heightened risk for serious gastrointestinal complications. Because of this heightened risk, regulatory guidance emphasizes that older adults should utilize the lowest effective dose for the shortest duration possible.

Q: What happens if you accidentally miss a dose of Panafen?

Official procedural rules state that if a scheduled dose is missed, it should be skipped if it is close to the time of the next dose. Taking a double dose is explicitly prohibited to make up for a missed one.

Q: Does Panafen affect the liver or kidneys?

Official regulatory documents list severe liver or kidney impairment as a contraindication. Patients with lesser degrees of impairment are often advised in the regulatory text to be monitored for signs of functional decline.

Q: Do you need a prescription to buy Panafen?

Panafen is commonly available for purchase over-the-counter (OTC) in many regions. However, certain higher strengths or specific formulations of the medication may be available only with a prescription.

Q: Is it normal to feel a tingling sensation after taking Panafen?

While a tingling sensation (paresthesia) is not listed as a common side effect, some official documents have noted infrequent reports of this nervous system effect.

Q: What should I do if I experience an allergic reaction to Panafen?

The medicine should be immediately discontinued if signs of a hypersensitivity reaction (such as difficulty breathing, swelling, or rash) occur. Since hypersensitivity is a contraindication, immediate medical attention is necessary.

Q: Are there any known interactions between Panafen and alcohol?

Yes, regulatory warnings state that combining the medicine with alcohol increases the risk of serious gastrointestinal complications, including stomach bleeding.

Q: Is Panafen effective for tension headaches and migraines?

Official indications for this medicine include the treatment of headaches. It is commonly utilized as an option for treating both tension headaches and mild to moderate migraine pain.

Q: Why is the dosage for children different from adults?

The official regulatory guidelines require that the dosage for children be calculated based on their body weight. This is done to ensure the dose is precise and minimizes risk, unlike the fixed-dose approach commonly used for adults.

Q: Can Panafen cause issues with sleeping patterns?

Official nervous system side effect profiles have occasionally reported instances of both sleepiness (somnolence) and sleeplessness (insomnia) in users of this medicine.

Q: Is there evidence that Panafen helps with arthritis pain?

Official indications and research documents show that this medicine is used as a therapeutic option for reducing pain and inflammation associated with chronic conditions, such as rheumatoid arthritis and osteoarthritis.

Q: Why do some people use Panafen for post-operative pain?

Panafen is officially indicated for the relief of mild to moderate pain. This indication covers the management of general discomfort and pain that may follow certain surgical or medical procedures.

Q: What are the signs of taking too much Panafen?

Signs of acute overdose can include symptoms such as drowsiness, disorientation, dizziness, and rapid, shallow breathing. Severe symptoms, such as profound coma or seizures, have been reported in the case of acute overdose.

Q: Can Panafen be used to treat the symptoms of the common cold or flu?

Panafen can be used to relieve common cold and flu-related symptoms. It is effective for reducing fever, alleviating headaches, and controlling general body aches, as indicated in its official uses.

Q: Why is it important to stay hydrated when taking Panafen?

Official warnings note that this medicine can be linked to fluid retention and carries a risk for renal (kidney) side effects. Maintaining appropriate hydration is generally advised when using medications that affect kidney function.

Q: How long after taking Panafen can I drive or operate machinery?

If side effects like dizziness or drowsiness are experienced after taking the medicine, the regulatory information advises caution. This is because the ability to drive or safely operate machinery may be temporarily impaired by these effects.

Storage Requirements

Official regulatory documents require that Panafen (ibuprofen) be stored in the container it came in, tightly closed, at room temperature and protected from excess heat and moisture to maintain stability. Oral forms must be kept from freezing and away from direct light. One specific oral suspension requires storage below 30°C.

Child-Safety and Handling

This medication must be stored out of the sight and reach of children using safety measures such as locking caps. Intravenous solutions are generally single-use and must be visually inspected for particulate matter prior to use.

Official Disposal Rules

Unwanted or expired medicine should be returned through an official drug take-back program. If this is unavailable, the medicine must be mixed with an unappealing substance like dirt or used coffee grounds, placed in a sealed bag, and discarded with household trash. Any unused medicinal waste must be disposed of according to local requirements.